A retrospective,single center study in highly sensitized pediatric renal transplant recipients to evaluate the safety and efficacy of Alemtuzumab induction
Latest Information Update: 13 Oct 2016
Price :
$35 *
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 13 Oct 2016 New trial record